Results 41 to 50 of about 15,406 (277)

Vigabatrin [PDF]

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1996
ABSTRACT:Vigabatrin (VGB) is a recently-released antiepileptic drug which works by a clearlydefined mechanism of action: inhibition of GABA transaminase leading to an elevation of brain GABA concentration. It has been proven effective, mainly as an add-on agent, in complex partial and secondarily generalized seizures in both adults and children as well
openaire   +2 more sources

Safety profile of oxcarbazepine: results from a prescription-event monitoring study [PDF]

, 2010
Purpose: To monitor safety of oxcarbazepine, prescribed in primary care in England, using prescription-event monitoring (PEM). Methods: Postmarketing surveillance using observational cohort technique of PEM.
Buggy, Y., Fogg, Carole, Layton, D., Shakir, S.   +3 more
core   +1 more source

Visual evoked potentials in succinate semialdehyde dehydrogenase (SSADH) deficiency [PDF]

, 2009
In mammals, increased GABA in the central nervous system has been associated with abnormalities of visual evoked potentials (VEPs), predominantly manifested as increased latency of the major positive component P100.
Blasi, P, Crutchfield, SR, Di Rosa, G, Dionisi-Vici, C, Gibson, KM, Malaspina, P, Rizzo, C, Tortorella, G   +7 more
core   +1 more source

Vigabatrin for focal drug delivery in epilepsy: Bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model

Neurobiology of Disease, 2012
Vigabatrin is a rationally developed antiepileptic drug, which acts by increasing GABA levels in the brain by irreversibly inhibiting GABA degradation.
Sonja Bröer, Bianca Backofen-Wehrhahn, Marion Bankstahl, Laura Gey, Manuela Gernert, Wolfgang Löscher   +5 more
doaj   +1 more source

Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents [PDF]

, 2012
Background Infantile spasms (IS; West syndrome) is a severe form of encephalopathy that typically affects infants younger than 2 years old. Pediatricians, pediatric neurologists, and other pediatric health care providers are all potentially key early ...
Gibson, Patricia A., Hardin, Maria, Luther Rosbeck, Kari, O’Dell, Christine, Pellock, John M., Wheless, James W., Whittemore, Vicky   +6 more
core   +2 more sources

Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin? [PDF]

, 2014
Purpose Vigabatrin (VGB) is an anti-epileptic medication which has been linked to peripheral constriction of the visual field. Documenting the natural history associated with continued VGB exposure is important when making decisions about the risk and
Conway, M. L., Cubbidge, P. R., Hosking, L. S., Zhu, H.   +3 more
core   +3 more sources

Vigabatrin-associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex. [PDF]

Epilepsia
Stevering C, Lequin M, Szczepaniak K, Sadowski K, Ishrat S, De Luca A, Leemans A, Otte W, Kwiatkowski DJ, Curatolo P, Weschke B, Riney K, Feucht M, Krsek P, Nabbout R, Jansen A, Wojdan K, Sijko K, Glowacka-Walas J, Borkowska J, Domanska-Pakiela D, Moavero R, Hertzberg C, Hulshof H, Scholl T, Petrák B, Maminak M, Aronica E, De Ridder J, Lagae L, Jozwiak S, Kotulska K, Braun K, Jansen F.   +33 more
europepmc   +3 more sources

Safety and Efficacy of Vigabatrin for the Treatment of Infantile Spasms

Journal of Central Nervous System Disease, 2011
In 2009, vigabatrin became the first FDA approved medication for the treatment of infantile spasms in the United States. There are few well-designed prospective studies comparing the drug to placebo or other modalities used in the treatment of infantile ...
Michele A. Faulkner, Justin A. Tolman
doaj   +1 more source

Scotopic threshold response changes after vigabatrin therapy in a child without visual field defects: a new electroretinographic marker of early damage?

Neurobiology of Disease, 2004
Vigabatrin (VGB) has been widely used in patients affected by drug-resistant epilepsy and West syndrome. Following reports of visual field loss associated with vigabatrin therapy, some authors have investigated retinal electrophysiologic variables to ...
Pasquale Parisi, Paolo Tommasini, Giuseppe Piazza, Mario Manfredi   +3 more
doaj   +1 more source

Vigabatrin-Induced Visual Field Defects

Pediatric Neurology Briefs, 1998
A drug surveillance database at Hoechst Marion Roussel, manufacturers of vigabatrin, identified 92 cases of symptomatic visual field defects associated with vigabatrin (usually as add-on therapy) between 1990 and 1997.
J Gordon Millichap
doaj   +1 more source